Cover Image

Splice variants of androgen receptor and prostate cancer

Orazio Caffo, Francesca Maines, Antonello Veccia, Stefania Kinspergher, Enzo Galligioni
  • Francesca Maines
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
  • Antonello Veccia
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
  • Stefania Kinspergher
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
  • Enzo Galligioni
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy

Abstract

Over the last ten years, two new-generation hormonal drugs and two chemotherapeutic agents have been approved for the treatment of metastatic castration-resistant prostate cancer. Unfortunately, some patients have primary resistance to them and the others eventually develop secondary resistance. It has recently been suggested that the presence of androgen receptor splice variants plays a leading role in the primary and secondary resistance to the new hormonal drugs, whereas their presence seem to have only a partial effect on the activity of the chemotherapeutic agents. The aim of this paper is to review the published data concerning the role of androgen receptor splice variants in prostate cancer biology, and their potential use as biomarkers when making therapeutic decisions.

Keywords

Prostate cancer; splice variants; enzalutamide; abiraterone; cabazitaxel.

Full Text:

PDF
HTML
Submitted: 2016-03-28 07:22:33
Published: 2016-05-30 10:40:09
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
988

Views:
PDF
412
HTML
421

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Orazio Caffo, Francesca Maines, Antonello Veccia, Stefania Kinspergher, Enzo Galligioni

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185